Monoaminergic and histaminergic strategies and treatments in brain diseases
The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson’s disease where the pathophysiology led almost immediately to the int...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-11-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00541/full |
| _version_ | 1828375958586916864 |
|---|---|
| author | Giuseppe Di Giovanni Dubravka Svob Strac Montse Sole Mercedes Unzeta Keith Francis Tipton Dorotea Mück-Šeler Irène Bolea Laura Della Corte Matea Nikolac Perkovic Nela Pivac Ilse Julia Smolders Anna Stasiak Wieslawa Agnieszka Fogel Philippe De Deurwaerdère |
| author_facet | Giuseppe Di Giovanni Dubravka Svob Strac Montse Sole Mercedes Unzeta Keith Francis Tipton Dorotea Mück-Šeler Irène Bolea Laura Della Corte Matea Nikolac Perkovic Nela Pivac Ilse Julia Smolders Anna Stasiak Wieslawa Agnieszka Fogel Philippe De Deurwaerdère |
| author_sort | Giuseppe Di Giovanni |
| collection | DOAJ |
| description | The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson’s disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from in vivo neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable treatments for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson’s disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer’s disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review. |
| first_indexed | 2024-04-14T07:54:13Z |
| format | Article |
| id | doaj.art-ca03d10c8f154678a9908f3f996bd1dd |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-04-14T07:54:13Z |
| publishDate | 2016-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-ca03d10c8f154678a9908f3f996bd1dd2022-12-22T02:05:06ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2016-11-011010.3389/fnins.2016.00541222966Monoaminergic and histaminergic strategies and treatments in brain diseasesGiuseppe Di Giovanni0Dubravka Svob Strac1Montse Sole2Mercedes Unzeta3Keith Francis Tipton4Dorotea Mück-Šeler5Irène Bolea6Laura Della Corte7Matea Nikolac Perkovic8Nela Pivac9Ilse Julia Smolders10Anna Stasiak11Wieslawa Agnieszka Fogel12Philippe De Deurwaerdère13University of Malta, MTRudjer Boskovic InstituteUniversitat Autònoma de BarcelonaUniversitat Autònoma de BarcelonaTrinity College DublinRudjer Boskovic InstituteUniversitat Autònoma de BarcelonaUniversity of FlorenceRudjer Boskovic InstituteRudjer Boskovic InstituteVrije Universiteit BrusselMedical University of LodzMedical University of LodzCentre National de la recherche scientifique (CNRS)The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson’s disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from in vivo neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable treatments for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson’s disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer’s disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review.http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00541/fullMonoamine Oxidase InhibitorsNeurodegenerative DiseasesStrokeantidepressantDrug Additionantiparkinsonian treatments |
| spellingShingle | Giuseppe Di Giovanni Dubravka Svob Strac Montse Sole Mercedes Unzeta Keith Francis Tipton Dorotea Mück-Šeler Irène Bolea Laura Della Corte Matea Nikolac Perkovic Nela Pivac Ilse Julia Smolders Anna Stasiak Wieslawa Agnieszka Fogel Philippe De Deurwaerdère Monoaminergic and histaminergic strategies and treatments in brain diseases Frontiers in Neuroscience Monoamine Oxidase Inhibitors Neurodegenerative Diseases Stroke antidepressant Drug Addition antiparkinsonian treatments |
| title | Monoaminergic and histaminergic strategies and treatments in brain diseases |
| title_full | Monoaminergic and histaminergic strategies and treatments in brain diseases |
| title_fullStr | Monoaminergic and histaminergic strategies and treatments in brain diseases |
| title_full_unstemmed | Monoaminergic and histaminergic strategies and treatments in brain diseases |
| title_short | Monoaminergic and histaminergic strategies and treatments in brain diseases |
| title_sort | monoaminergic and histaminergic strategies and treatments in brain diseases |
| topic | Monoamine Oxidase Inhibitors Neurodegenerative Diseases Stroke antidepressant Drug Addition antiparkinsonian treatments |
| url | http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00541/full |
| work_keys_str_mv | AT giuseppedigiovanni monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT dubravkasvobstrac monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT montsesole monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT mercedesunzeta monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT keithfrancistipton monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT doroteamuckseler monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT irenebolea monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT lauradellacorte monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT mateanikolacperkovic monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT nelapivac monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT ilsejuliasmolders monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT annastasiak monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT wieslawaagnieszkafogel monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases AT philippededeurwaerdere monoaminergicandhistaminergicstrategiesandtreatmentsinbraindiseases |